Last reviewed · How we verify
R-EPOCH and cART
At a glance
| Generic name | R-EPOCH and cART |
|---|---|
| Also known as | Rituxan, Vepesid, Adriamycin, Vincristine, Cytoxan |
| Sponsor | Ontario Clinical Oncology Group (OCOG) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of CAR-T Therapy in Older Patients
- Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies (NA)
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-EPOCH and cART CI brief — competitive landscape report
- R-EPOCH and cART updates RSS · CI watch RSS
- Ontario Clinical Oncology Group (OCOG) portfolio CI